logo
Share SHARE
FONT-SIZE Plus   Neg

Aeterna Zentaris' Phase3 Perifosine Trial Fails To Meet Primary Endpoint

Late-stage oncology drug development company Aeterna Zentaris Inc. (AEZS, AEZ.TO) said its Phase 3 trial evaluating perifosine in refractory advanced colorectal cancer patients failed to meet primary endpoint. Trading for Aeterna halted in early morning hours and shares are currently down more than 55 percent on the Nasdaq.

The focus of the X-PECT study was improvement of overall survival with perifosine in comparison with capecitabine + placebo. The trial involved 468 patients in 65 sites in the U.S and the study was conducted by the Company's North American licensee partner, Keryx Biopharmaceuticals, Inc. (KERX).

Aeterna Zentaris said it is very disappointed that the trial result. The company will continue further data analyses in collaboration with our licensee partners, in order to determine the future development strategy for perifosine.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
As the din settles down on a dismal quarter at one of the world's exciting tech company, it is time to sit back and take stock of what went wrong and will the wrong be righted in the near term? Online movie rental service Netflix Inc., in a blog post on Thursday, said it is offering a new tool to better control data usage when streaming on cellular networks. The feature helps subscribers switch from default speed to higher-quality streams. Netflix's updated app on iOS or Android now has a default streaming speed of 600 kilobits-per-second for all users. The U.S. Food and Drug Administration Thursday announced it will start regulating all tobacco products, including e-cigarettes, cigars, hookah tobacco and pipe tobacco, just like it regulates cigarettes. Under the new rules, e-cigarettes manufacturers should receive marketing authorization from the...
comments powered by Disqus
Follow RTT